Exploring the role and function of trial steering committees: results of an expert panel meeting. Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Harman, Nicola; Conroy, Elizabeth; Lewis, Steff; Murray, Gordon; Norrie, John; Sydes, Matt; Lane, J.; Altman, Douglas; Baigent, Colin; Bliss, Judith; Campbell, Marion; Elbourne, Diana; Evans, Stephen; Sandercock, Peter; Gamble, Carrol
• Is Part Of: Trials. Volume 16:Issue 1(2015)
• Page Start: 1
• Page End: 14
• Publication Date: 2015-12
• Subjects: Trials -- oversight committee -- trial steering committee -- executive committee -- clinical trial -- data monitoring committee -- terms of reference -- randomised controlled trial; Group-randomized trials -- Periodicals; Randomized Controlled Trials -- Periodicals; 615.0727
• DOI: 10.1186/s13063-015-1125-z
• Languages: English
• ISSNs: 1745-6215

Abstract

Abstract Background The independent oversight of clinical trials, which is recommended by the Medical Research Council (MRC) Guidelines for Good Clinical Practice, is typically provided by an independent advisory Data Monitoring Committee (DMC) and an independent executive committee, to whom the DMC makes recommendations. The detailed roles and function of this executive committee, known as the Trial Steering Committee (TSC), have not previously been studied or reviewed since those originally proposed by the MRC in 1998. Methods An expert panel (n = 7) was convened comprising statisticians, clinicians and trial methodologists with prior TSC experience. Twelve questions about the role and responsibilities of the TSC were discussed by the panel at two full-day meetings. Each meeting was transcribed in full and the discussions were summarised. Results The expert panel reached agreement on the role of the TSC, to which it was accountable, the membership, the definition of independence, and the experience and training needed. The management of ethical issues, difficult/complex situations and issues the TSC should not ask the DMC to make recommendations on were more difficult to discuss without specific examples, but support existed for further work to help share issues and to provide appropriate training for TSC members. Additional topics discussed, which had not been identified by previous work relating to the DMCs but were pertinent to the role of the TSC, included the following: review of data sharing requests, indemnity, lifespan of the TSC, general TSC administration, and the roles of both the Funder and the Sponsor. Conclusions This paper presents recommendations that will contribute to the revision and update of the MRC TSC terms of reference. Uncertainty remains in some areas due to the absence of real-life examples; future guidance on these issues would benefit from a repository of case studies. Notably, the role of a patient and public involvement (PPI) contributor was not discussed, and further work is warranted to explore the role of a PPI contributor in independent trial oversight.